Bukwang Pharmaceutical announced on the 29th that it has shipped its first contract-manufactured pharmaceutical product in collaboration with Union Korea Pharm.


Bukwang Pharmaceutical outsourced the production of pharmaceuticals to Union Korea Pharm and shipped the 'Fajyme Tab. (active ingredient: pancreatin)' on the 26th. Fajyme Tab., an over-the-counter medication, is used for gastrointestinal purposes and is effective for indigestion and abdominal bloating caused by loss of appetite. In addition, 'Hardcal Chewable Tab. (active ingredient: calcium carbonate)' and 'Hardcal Chewable Easy Tab.', both over-the-counter drugs for thyroid and endocrine use, will also be produced by Union Korea Pharm and are scheduled to be shipped starting in August.


Seoul Dongjak-gu Bukwang Pharmaceutical Headquarters Building. Bukwang Pharmaceutical

Seoul Dongjak-gu Bukwang Pharmaceutical Headquarters Building. Bukwang Pharmaceutical

View original image

A Bukwang Pharmaceutical official stated, "Fajyme Tab. was a pharmaceutical product that was outsourced due to Bukwang Pharmaceutical's insufficient production capacity," adding, "Going forward, this product will be fully manufactured by Union Korea Pharm, and we plan to outsource the production of other pharmaceuticals to them within this year as well."


The official continued, "Union Korea Pharm is striving to enhance its performance by starting the contract manufacturing (CMO) business with Bukwang Pharmaceutical's products," and added, "Currently, Union Korea Pharm is already discussing contract pharmaceutical manufacturing with several other pharmaceutical companies."


Meanwhile, Union Korea Pharm's corporate rehabilitation termination process is proceeding smoothly. Previously, Union Korea Pharm planned to hold an extraordinary general meeting of shareholders regarding the appointment and dismissal of executives on the 23rd. However, due to a delay in the electronic registration of new shareholders from the debt-to-equity swap, the meeting has been postponed to the 21st of next month.



A Bukwang Pharmaceutical official said, "Only the final procedures for rehabilitation termination remain," adding, "With the paid-in capital increase taking effect on May 28, the day after the acquisition balance payment, the acquisition was effectively completed on that date." The official further stated, "The normalization plan for Union Korea Pharm after the acquisition is proceeding smoothly without issues. We will continue to strictly adhere to the court's management procedures and achieve rapid business normalization through synergy with the new Union Korea Pharm."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing